<div id="readability-page-1"><p>Delphi Financial Group Inc. purchased a new position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 660,852 shares of the company's stock, valued at approximately $430,000. Cartesian Therapeutics comprises 0.3% of Delphi Financial Group Inc.'s investment portfolio, making the stock its 23rd biggest holding. Delphi Financial Group Inc. owned about 12.26% of Cartesian Therapeutics as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Cartesian Therapeutics</strong> alerts:</span></p></div><p>Separately, Hall Laurie J Trustee bought a new stake in Cartesian Therapeutics in the 1st quarter valued at about $34,000. Institutional investors and hedge funds own 86.95% of the company's stock. </p><h2>Cartesian Therapeutics Trading Down 0.2 %</h2><p>Shares of NASDAQ RNAC traded down $0.04 during trading on Tuesday, reaching $16.78. The company had a trading volume of 399,320 shares, compared to its average volume of 88,681. Cartesian Therapeutics, Inc. has a 12-month low of $11.66 and a 12-month high of $42.60. The business's 50-day moving average is $25.75 and its 200 day moving average is $22.34. </p><p>Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($1.97) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($1.16). The firm had revenue of $5.84 million during the quarter. As a group, equities analysts forecast that Cartesian Therapeutics, Inc. will post 2.28 EPS for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of research firms have weighed in on RNAC. Oppenheimer lowered Cartesian Therapeutics from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Tuesday, July 2nd. Mizuho assumed coverage on Cartesian Therapeutics in a research report on Friday, May 24th. They issued a &#34;buy&#34; rating and a $40.00 price objective for the company. Leerink Partnrs reiterated an &#34;outperform&#34; rating on shares of Cartesian Therapeutics in a research report on Tuesday, April 23rd. SVB Leerink assumed coverage on Cartesian Therapeutics in a report on Tuesday, April 23rd. They set an &#34;outperform&#34; rating and a $39.00 target price for the company. Finally, Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $42.00 price objective on shares of Cartesian Therapeutics in a report on Monday. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, Cartesian Therapeutics has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $43.83.</p><p><b>View Our Latest Stock Report on RNAC</b></p><h2>Cartesian Therapeutics Profile</h2> (Free Report)<p>Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.</p><h2>See Also</h2><ul><li>Five stocks we like better than Cartesian Therapeutics</li><li>How to Most Effectively Use the MarketBeat Earnings Screener</li><li>3 Insider-Buy Stocks to Add to Your Watchlist Now</li><li>How to Find Undervalued Stocks</li><li>Commvault Stock: AI Cybersecurity Giant Ready to Double Again</li><li>What is a Bond Market Holiday? How to Invest and Trade</li><li>Intuit Stock Ready to Soar: RBC Sees Big Upside with GenAI</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Trader behind 1,129% profit reveals new AI <span><span>(From Monument Traders Alliance)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzAy"/></p><h2>Should you invest $1,000 in Cartesian Therapeutics right now?</h2><p>Before you consider Cartesian Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cartesian Therapeutics wasn't on the list.</p><p>While Cartesian Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

RNAC

<p>Delphi Financial Group Inc. has acquired a new position in Cartesian Therapeutics, Inc. The firm purchased 660,852 shares of the company's stock, valued at approximately $430,000. Cartesian Therapeutics is a clinical-stage biotechnology company that develops mRNA cell therapies for autoimmune diseases. The stock has a 12-month low of $11.66 and a 12-month high of $42.60.</p>

Delphi Financial Group Inc. Acquires New Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)